Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

Journal of the American Academy of Dermatology

Volumn 74, Issue 1, 2016, Pages 190-192

  Danesh, Melissa J ^a,c   Kimball, Alexa B ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c San Francisco Telecom   (United States)

Author keywords

anti IL 17RA; brodalumab; depression; economic recession; monoclonal antibody; suicidal ideation; suicide

Indexed keywords

BRODALUMAB; MONOCLONAL ANTIBODY;

DEPRESSION; ECONOMIC RECESSION; HUMAN; MORTALITY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SHORT SURVEY; SUICIDAL IDEATION; SUICIDE; UNEMPLOYMENT; UNITED STATES; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ADMINISTRATION; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECONOMIC RECESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SUICIDAL IDEATION; SUICIDE; UNITED STATES;

EID: 84953408338     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.08.057     Document Type: Editorial

References (9)

1. Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12. Poster session presented at the 73rd Annual American Academy of Dermatology Meeting, San Francisco, California, March 2015.
2. National Center for Health Statistics. Underlying cause of death 1999-2013. Available from: URL: http://wonder.cdc.gov/wonder/help/ucd.html. Accessed June 28, 2015.
3. S. Tyring, A. Gottlieb, K. Papp, and et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial Lancet 367 9504 2006 29 35
4. K.A. Papp, J. Signorovitch, K. Ramakrishnan, and et al. Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicenter clinical trials Clin Drug Investig 31 1 2011 51 60
5. K.A. Fowler, R.M. Gladden, K.J. Vagi, and et al. Increase in suicides associated with home eviction and foreclosure during the US housing crisis: findings from 16 National Violent Death Reporting System States, 2005-2010 Am J Public Health 105 2 2015 311 316
6. A. Reeves, D. Stuckler, M. McKee, and et al. Increase in state suicide rates in the USA during economic recession Lancet 380 9856 2012 1813 1814
7. World Health Organization. Mortality database. Available from: URL: http://apps.who.int/healthinfo/statistics/mortality/whodpms/. Accessed July 8, 2015.
8. E.J. Horn, K.M. Fox, V. Patel, and et al. Association of patient-reported psoriasis severity with income and employment J Am Acad Dermatol 57 6 2007 963 971
9. Celgene Corporation. Highlights of prescribing information. Available from: URL: http://www.otezla.com/otezla-prescribing-information.pdf. Accessed July 5, 2015.